Clinical trials
catalyst calendar across sponsors →Studies where RGEN is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
6 interventional
Held by 17 tracked-famous managers (MAVERICK CAPITAL LTD, Holocene Advisors, LP, CITADEL ADVISORS LLC, Balyasny Asset Management L.P., PRIMECAP MANAGEMENT CO/CA/, +12 more) · FINRA short interest 3.9 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 1 sells · government filings 180d: 0 congress / 1 executive
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| A Study to Assess the Safety, Tolerability and Efficacy of RG2417 in Bipolar I DepressionNCT00812058MADRS ScoreRandomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: RG2417, Placebo | Bipolar I Depression | 180 | Dec 2010actual | 2011-01-17 |
| Safety and Efficacy of Synthetic Human Secretin-Enhanced MRCP in Subjects With Abnormalities of the PancreasNCT00660335The primary outcome measure will be assessed by comparing baseline MRCP images and RG1068-enhanced MRCP images for the presence or absence of pancreatic abnormalities.Open-label · Diagnostic | Phase 3 | Completed | Drug: RG1068 (synthetic human secretin) | Pancreatitis | 258 | Oct 2009actual | 2009-12-03 |
| Synthetic Human Secretin in Children With Autism and Gastrointestinal DysfunctionNCT00036231Randomized · Double-masked · Treatment | Phase 3 | Terminated | Drug: RG1068 (Synthetic Human Secretin) | Autism | — | — | 2005-11-21 |
| Synthetic Human Secretin in Children With AutismNCT00036244Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: RG1068 (Synthetic Human Secretin) | Autism | — | — | 2005-08-05 |
| RG2133 (2',3',5'-Tri-O-Acetyluridine) in Mitochondrial DiseaseNCT00060515Non-randomized · Treatment | Phase 1 | Terminated | Drug: RG2133 (2',3',5'-tri-O-acetyluridine) | Mitochondrial Diseases | 12 | — | 2005-08-05 |
| Phase II Study to Assess RG2417 in the Treatment of Bipolar I DepressionNCT00322764Improvement of MADRS and CGI BP C for RG2417 treatment in comparison to placeboRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Uridine | Bipolar Depression | 80 | — | 2007-11-09 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19